As per a study conducted by Nakamura et al. (2013), titled “Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy)”, by February 2012, 105 Becker Muscular Dystrophy patients were registered. Most individuals aged less than 20 years. In terms of genetic mutations of registrants of Becker Muscular Dystrophy, deletion of exons was the most frequent (61.4% and 79.0%) followed by point mutations (24.5% and 14.3%) and duplications (13.6% and 4.8%), respectively and 76.2% of Becker Muscular Dystrophy registrants were able to walk.
The Becker Muscular Dystrophy market is set to evolve immensely in the coming years due to the rising awareness of the disease and incremental healthcare spending worldwide, which would expand the market size to enable drug manufacturers to penetrate more into the market.
The pharmaceutical giants and academics are working to assess challenges and seek opportunities that could influence Becker Muscular Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
DelveInsight’s “Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Becker Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Becker Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Becker Muscular Dystrophy Overview
Becker Muscular Dystrophy (BMD) is an inherited disorder affecting muscle structure, leading to progressive degeneration of limbs, cardiac, and skeletal muscles. Unlike involuntary muscles, those under conscious control remain unaffected. Considered a milder form of Duchenne Muscular Dystrophy (DMD), BMD typically manifests in adolescence or early adulthood, with a slower and less predictable progression compared to DMD.
Early signs of BMD include post-exercise cramps, while later symptoms may involve difficulties in walking briskly or running. Additional noticeable indicators include falls, fatigue, and skeletal changes. Muscle weakness, commonly impacting the legs and pelvis, worsens gradually. While some individuals may experience minor learning difficulties, they are less common.
BMD results from mutations in the DMD gene, an X-linked disorder carried by females. These mutations lead to the production of faulty dystrophin protein, which normally supports and protects muscle fibers, as well as aids in cellular signaling. Without functional dystrophin, muscle cells deteriorate during contraction and relaxation, leading to weakness and eventual muscle loss, alongside potential heart complications.
Primarily affecting males, the age of onset and progression rate vary. Muscle weakness typically emerges between 5 and 15 years old. In some instances, cardiomyopathy may present as the initial symptom, weakening the heart muscle and impairing blood pumping efficiency. Over time, this can progress to dilated cardiomyopathy, characterized by enlarged heart muscles and further cardiac complications.
Becker Muscular Dystrophy Market Key Facts
-
According to the Genetic and Rare Diseases Information Center, the prevalence of Becker Muscular Dystrophy is estimated to be between 17–27 cases per million people. This means that at a given time, about one in 37,000 to one in 59,000 people are living with Becker Muscular Dystrophy.
-
According to the Centers for Disease Control and Prevention (CDC), the estimated prevalence of Duchenne and Becker muscular dystrophy (DBecker Muscular Dystrophy) was one in every 7,250 males aged 5–24 years. However, the prevalence of DMD was found to be three times higher than the prevalence of Becker Muscular Dystrophy.
Becker Muscular Dystrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Becker Muscular Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Becker Muscular Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Becker Muscular Dystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Becker Muscular Dystrophy Epidemiology, Segmented as –
-
Prevalent Cases of BMD in the 7MM (2019–2032)
-
Age-specific Prevalent Cases of BMD in the 7MM (2019–2032)
-
Diagnosed and Treatable Cases of BMD in the 7MM (2019–2032)
Becker Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Becker Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the Becker Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Becker Muscular Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Becker Muscular Dystrophy Therapeutics Analysis
Several major pharma and biotech players are involved in developing Becker Muscular Dystrophy therapies. The launch of emerging therapies is anticipated to impact the Becker Muscular Dystrophy market significantly. Moreover, a better understanding of Becker Muscular Dystrophy pathogenesis will also contribute to developing novel therapeutics for Becker Muscular Dystrophy.
Currently, Italfarmaco is leading the therapeutics market with its Becker Muscular Dystrophy drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Becker Muscular Dystrophy Therapeutics Market Include:
-
Edgewise Therapeutics
-
Epirium Bio
-
ImmunoForge
-
Italfarmaco
-
PTC Therapeutics
-
ReveraGen biopharma
-
Strykagen
-
Ultragenyx
And Many Others
Becker Muscular Dystrophy Emerging and Marketed Drugs Covered in the Report Include:
-
EDG 5506 : Edgewise Therapeutics
-
Epicatechi: Epirium Bio
-
Givinostat: Italfarmaco
-
PF1801: ImmunoForge
-
Translarna: PTC Therapeutics
-
Vamorolone: ReveraGen biopharma
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/becker-muscular-dystrophy-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Becker Muscular Dystrophy Competitive Intelligence Analysis
4. Becker Muscular Dystrophy Market Overview at a Glance
5. Becker Muscular Dystrophy Disease Background and Overview
6. Becker Muscular Dystrophy Patient Journey
7. Becker Muscular Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Becker Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Becker Muscular Dystrophy Unmet Needs
10. Key Endpoints of Becker Muscular Dystrophy Treatment
11. Becker Muscular Dystrophy Marketed Products
12. Becker Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Becker Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Becker Muscular Dystrophy Market Outlook (In US, EU5, and Japan)
16. Becker Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Becker Muscular Dystrophy Market
18. Becker Muscular Dystrophy Market Drivers
19. Becker Muscular Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Download the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/becker-muscular-dystrophy-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/